Levomycetin

Quick links to important sections

Levomycetin

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levomycetin

Property Description
Active Ingredient Chloramphenicol
Form Tablets, capsules, injections, drops, ointments
Pharmacological Class Broad-spectrum bacteriostatic antibiotic
General Purpose Management of bacterial infections
Origin Synthetic (nitrobenzene derivative)

Defining the Core Antibiotic Entity

Levomycetin is the medicinal entity whose active ingredient is the chemical compound Chloramphenicol, which is classified as a potent broad-spectrum bacteriostatic antibiotic. This compound is a synthetic agent, manufactured as a nitrobenzene derivative.

As a bacteriostatic agent, its primary function is to halt the growth and multiplication of susceptible bacteria, rather than immediately killing them. Pharmacological studies confirm that Chloramphenicol's bacteriostatic mechanism provides essential coverage against a wide range of pathogens, a property clinically recognized for its effectiveness in specific serious infections where resistance to other antibiotics is present.

Composition and Available Pharmaceutical Forms

The core composition of Levomycetin relies on the single active component Chloramphenicol, prepared with various carriers, typically as a single-ingredient product.

To accommodate diverse therapeutic needs, Levomycetin is manufactured in several forms, ensuring flexible delivery for both internal and external use. These forms include oral preparations like tablets and capsules, alongside specialized localized treatments such as eye and ear drops and ophthalmic/topical ointments. This broad availability allows the drug to address both systemic infections via oral/parenteral routes and localized conditions, such as bacterial conjunctivitis, through its topical forms.

General Therapeutic Purpose

The general purpose of Levomycetin is to provide essential control over bacterial infections caused by a broad spectrum of susceptible microorganisms. Its therapeutic benefit is rooted in its specific action: the active compound selectively binds to the 50S ribosomal subunit within the bacterial cell, blocking the protein synthesis required for the microbe's growth and proliferation. This mechanism effectively suppresses the infection's ability to spread, which is the foundational basis for its established clinical use.

Regulatory References

  1. NIH StatPearls - Chloramphenicol

What side effects are possible with Levomycetin?

Possible side effects and safety information

Officially Documented Adverse Reactions

The medicine's safety profile is defined by officially documented adverse reactions classified across several system-organ classes. The most critical regulatory concern involves Blood and Lymphatic System Disorders.

System-Organ Class Examples of Documented Effects
Blood Disorders Reversible Bone Marrow Depression, Hypoplastic Anemia, Thrombocytopenia, Granulocytopenia
Nervous System Headache, Mild Depression, Mental Confusion, Optic Neuritis, Peripheral Neuritis
Gastrointestinal Nausea, Vomiting, Diarrhea, Glossitis, Stomatitis, Enterocolitis
Immune System Fever, Rashes, Angioedema, Urticaria, Anaphylaxis (Hypersensitivity)

Serious Adverse Reactions and Safety Patterns

The regulatory safety documents specifically identify Aplastic Anemia as a serious, rare, and generally irreversible blood dyscrasia, reported following both systemic and topical use. This condition may appear weeks or months after therapy is complete.

Another specific serious toxic reaction, known as the "Gray Syndrome," is documented in neonates and premature infants, reflecting a constraint based on the age group's capacity for drug metabolism. The risk of dose-related, Reversible Bone Marrow Depression is commonly observed during therapy.

Population-Specific Safety Constraints

Safety notes for specific populations are documented in official labeling. Due to the risk of fetal and neonatal toxicity, use during pregnancy and lactation is generally advised against. Patients with hepatic or renal impairment may be at risk of excessive drug levels, a factor constraining administration. Concomitant use with other medicinal products known to depress bone marrow function is documented as a safety risk.

Overdose and Emergency Response

Documented Overdose Manifestations

Official regulatory sources define the overdose profile of Levomycetin (Chloramphenicol) as possessing the potential for severe, life-threatening systemic toxicity. Overdose or high serum concentrations are documented to present with systemic signs such as vomiting, diarrhea, abdominal distention, and central nervous system effects including drowsiness. The most critical toxic manifestation is the Gray Syndrome, predominantly affecting neonates and infants. This syndrome is characterized by progressive pallid cyanosis, hypothermia, and irregular respiration, documented as potentially escalating to cardiovascular collapse and death. Severe toxicity is also associated with findings of metabolic acidosis.

Mandatory Emergency Response

Regulatory guidance explicitly states that any suspected overdose requires the individual to seek immediate medical attention due to the serious nature of the potential outcomes. Management procedures mandate the discontinuation of the drug immediately upon the appearance of toxic symptoms. Treatment is strictly symptomatic and supportive, as official prescribing information states that no specific antidote is known for Chloramphenicol overdose. Hospital monitoring is required for observation of the systemic effects. Neonates and infants are noted as the population at highest risk for severe toxicity due to their documented capacity constraints in drug metabolism.

Therapeutic Uses of Levomycetin

What Levomycetin Treats: Main Uses and Benefits

Levomycetin (Chloramphenicol) may be part of symptomatic management and is applied across domains where additional symptomatic support is needed. Its use is relevant in clinical settings that involve acute or unstable symptom patterns.

Targeting Severe Systemic Illness and High-Risk Infections

The medication is relevant in conditions marked by increased physiological stress, such as serious systemic diseases, severe forms of typhoid fever, certain types of bacterial meningitis, and specific rickettsial diseases. The key benefit assists with maintaining functional stability and helps address symptoms related to systemic imbalance associated with severe illness.

Essential Use Against Drug-Resistant Bacteria

In contexts of bacterial resistance, its therapeutic role is applicable within clinical settings that involve acute or disruptive symptom patterns. This offers symptomatic relief that helps patients cope more steadily with difficult episodes by being applied when conditions produce significant symptomatic burden where other options may not be appropriate.

Addressing Localized Eye and Ear Bacterial Symptoms

The topical formulations are commonly used to help with managing symptoms that interfere with daily comfort, associated with infections like conjunctivitis and otitis externa. This contributes to easing the overall symptom load by addressing localized symptoms related to inflammatory or irritative states such as redness, discharge, and irritation, and supports improved comfort to the affected area.


Quick Fact: Symptomatic Support

Levomycetin is primarily used in conditions characterized by periods of heightened symptoms linked to severe systemic illness. Its use assists with maintaining functional stability during critical symptomatic phases.

Regulatory References

  1. NIH National Library of Medicine overview

Eligibility and Restrictions for Use

Levomycetin (Chloramphenicol) use is strictly controlled and reserved only for specific severe infections where other antibiotics are unsuitable. Official regulatory documents define clear populations who must not use the medicine.

Contraindicated Populations

Use of this medicine is contraindicated in individuals with a history of blood dyscrasias, including aplastic anaemia, or those who have previously experienced myelosuppression from Chloramphenicol. It must also not be used if the patient is taking other bone marrow-depressant drugs, or if there is a known hypersensitivity to the drug.

Age and Physiological Restrictions

Systemic use is generally contraindicated for pregnant individuals and breastfeeding mothers due to the risk of fetal and infant toxicity, specifically the Gray Baby Syndrome. Use in neonates and premature infants requires extreme caution and is conditional upon frequent monitoring of plasma drug levels.

Conditional Use and Restrictions

In patients with hepatic (liver) or severe renal (kidney) impairment, official labeling mandates use be conditional upon dose adjustment and rigorous plasma concentration monitoring. The medicine is also not recommended for treating trivial infections or for use as a preventative (prophylactic) agent.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Levomycetin (Chloramphenicol) has documented interaction patterns based on its potent inhibition of Cytochrome P450 enzymes, specifically CYP3A4 and CYP2C19, as noted in regulatory prescribing information. This pharmacokinetic interaction results in decreased clearance and potentially increased plasma concentrations of co-administered medicines that are metabolized by these enzymes.

Documented Interaction Categories

Category Official Regulatory Statement
Metabolic Inhibition Potent inhibition of CYP3A4 and CYP2C19, reducing the clearance of drugs like Phenytoin, Tacrolimus, and Cyclosporine
Pharmacodynamic Toxicity Avoid concomitant administration with other known bone marrow depressants due to an officially recognized risk of additive hematological toxicity (blood dyscrasias)
Anticoagulant Effects Co-administration may increase the effect of oral anticoagulants (e.g., Warfarin, Dicumarol)
Substance Interactions Official summaries advise caution regarding the use of alcohol or tobacco products as interactions may occur

Population-Specific Consideration

Regulatory documents identify a unique clearance delay risk in neonates and infants due to immature hepatic metabolism. This factor can lead to the drug accumulating to toxic concentrations if not properly managed, which is a key interaction-related consideration for this population.

Mechanism of Action

How Levomycetin Works at the Molecular Level

Levomycetin (Chloramphenicol) acts by binding to the bacterial ribosome to arrest protein synthesis. This mechanism is defined by its precise molecular target and the resulting cellular consequence.


Inhibiting Bacterial Protein Synthesis

Levomycetin acts as a reversible inhibitor by binding specifically to the 50S ribosomal subunit of susceptible bacteria, particularly at the Peptidyl Transferase Center (PTC). This binding physically prevents the peptidyl transferase enzyme from catalyzing the necessary transfer of the growing polypeptide chain, effectively blocking the elongation phase of bacterial protein synthesis.


Arrest of Cellular Growth and Division

This molecular interference causes a cellular cascade. By arresting the translation process, Levomycetin prevents the synthesis of critical proteins, including metabolic enzymes, structural components, and replication factors. This failure to synthesize essential proteins causes a state of bacterial stasis—the cell cannot undergo cellular growth or division. The physiological consequence is a deficit of critical proteins, inhibiting the potential for bacterial population expansion.

Dosage and Administration Information

How to Use Levomycetin (Chloramphenicol) — Official Administration Guidelines

This section outlines the administration instructions for Levomycetin (Chloramphenicol).


Administration Scope

Category Official Instruction
Route of Administration Oral, Intravenous (IV) for systemic use (Sodium Succinate form), and Topical/Ophthalmic (drops, ointment). The IV form must not be used Intramuscularly (IM).
Dosing Schedule & Frequency The standard systemic adult dose is typically 50 mg/kg/day in four equal divided doses administered every 6 hours (q6h).
Timing in Relation to Meals Oral capsules are generally best taken on an empty stomach (e.g., 1 hour before or 2 hours after meals) with water.
Preparation Requirements The powder for IV injection must be reconstituted with a suitable diluent, such as Water for Injection or 5% Dextrose Injection, before use.

Population-Specific & Procedural Rules

  • Age-Group Administration: Dosage must be significantly reduced for neonates and infants (typically to 25 mg/kg/day) and requires careful adjustment for the elderly and patients with hepatic or renal impairment.
  • Special Procedural Conditions: The IV solution must be administered slowly, typically over approximately one minute. For systemic infections, patients should be switched from IV to oral administration as soon as clinically practical. Topical treatment for eye infections must continue for at least 48 hours after the eye appears normal.

Official Procedural Summary: Dosing must begin with the correct form and calculated dose based on body weight, then strictly follow the every-6-hour schedule. The IV form requires reconstitution and slow injection. Doses are subject to mandatory reduction for newborns and patients with reduced organ function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Ocular and Topical Infections

Studies have investigated changes in symptoms of common bacterial infections in participants receiving Levomycetin (Chloramphenicol) for topical use. Research has examined its continued role in managing external ocular infections, such as bacterial conjunctivitis, where susceptibility to the antibiotic remains high. In these settings, Levomycetin is often utilized due to its broad spectrum of activity against many common pathogens.

  • Primary Studies: Clinical trials focusing on eye drops and ointments have shown that symptom resolution and bacterial clearance rates vary depending on the specific pathogen and the concentration used. The main finding is that Levomycetin remains a viable option for acute superficial infections when administered appropriately.

  • Topical Applications: Research has also explored the use of Levomycetin for certain skin infections, particularly in resource-limited settings. Data from smaller studies track resolution rates and local tolerability.

Mechanism and Safety Profile

Mechanism of Action

Studies were designed to examine the drug’s intended action, which involves interfering with bacterial protein synthesis by binding to the 50S ribosomal subunit. The focus of recent research is the prevalence of drug-resistant strains.

Hematological Safety

Due to historical concerns, research continues to evaluate the risk profile associated with Levomycetin, particularly rare but serious hematological events. Studies consistently note that the incidence of aplastic anemia is extremely low with short-course topical and ophthalmic administration, though the risk remains a key area of safety surveillance.

Important Research Note on Resistance

It is important to note that studies evaluating this antibiotic consistently highlight the growing issue of antimicrobial resistance across various geographical regions, which influences its practical clinical utility.

Frequently Asked Questions (FAQ)

Common questions about Levomycetin (FAQ)

Q: Why is Levomycetin sometimes referred to as a 'last resort' antibiotic?

A: Official documents indicate that systemic (oral or intravenous) Levomycetin is typically reserved for severe infections where less toxic antibiotics are ineffective or cannot be used. This cautious approach is due to the historically recognized risk of serious, irreversible blood disorders, such as aplastic anemia, and a serious toxic reaction in infants known as Gray Baby Syndrome.


Q: Is the risk of aplastic anemia higher with oral Levomycetin versus topical drops or ointment?

A: Regulatory decisions reflect that the risk of fatal aplastic anemia was highest with oral forms of the drug, leading to the withdrawal of these products in some jurisdictions. Official information confirms that the risk of aplastic anemia is considered extremely low when Levomycetin is used topically (as eye drops or ointment).


Q: How long after stopping Levomycetin can serious side effects potentially occur?

A: According to official safety documents, a very serious, rare blood disorder called aplastic anemia may appear not just during treatment, but also weeks or months after a person has stopped using the medicine. Official information highlights the importance of being aware of signs of blood disorders even after therapy is complete.


Q: What does it mean if a person experiences numbness or tingling in their hands or feet during treatment?

A: Numbness or tingling sensations in the hands or feet can be a sign of a documented side effect called peripheral neuritis, which involves the nerves in the extremities. This is listed under nervous system effects in the medicine's safety profile.


Q: What is the significance of the boron content sometimes found in Levomycetin eye drops?

A: Some ophthalmic formulations of Levomycetin include borax and boric acid as buffers to maintain the solution's stability. Regulatory agencies have reviewed the use of these ingredients and concluded that the amount of boron a person is exposed to from the eye drops is typically well below established safety limits.


Q: Are there any research themes currently exploring the long-term safety profile of Levomycetin?

A: Research has focused on the long-term safety profile of Levomycetin, particularly by examining the relationship between exposure and the potential for developing serious blood conditions like aplastic anemia or leukemia in susceptible groups, such as children. This ongoing area of study influences current guidance on who can use the medication.


Q: Does Levomycetin interact with hormonal birth control pills?

A: Official interaction information indicates that Levomycetin can potentially affect the metabolism of certain hormonal medications, including those used for birth control. This interaction may potentially reduce the effectiveness of the hormonal medication, which is a factor to consider regarding the risk of pregnancy or breakthrough bleeding.


Q: Are there any specific foods or drinks that should be avoided during Levomycetin use?

A: Regulatory summaries advise caution regarding the use of alcohol and tobacco products while using Levomycetin because interactions may occur. There are no official warnings or restrictions documented regarding specific foods to avoid.


Q: Is Levomycetin used to treat viral infections like the cold or flu?

A: No. Official regulatory warnings state that Levomycetin should not be used in the treatment of viral illnesses such as the common cold, influenza, or infections of the upper respiratory tract. It is an antibiotic designed to treat bacterial infections only.


Q: What is the difference between Levomycetin eye drops and the eye ointment?

A: The primary difference is the consistency, which affects how long the medication stays in the eye. The eye ointment is thicker and remains in place longer, often requiring less frequent application. Eye drops are usually clearer upon application, while the ointment can temporarily cause blurred vision immediately after use.


Q: Can Levomycetin be used to treat ear infections or is it strictly for eye use?

A: Yes, in addition to ophthalmic (eye) use, the medicine is also available as an otic solution (ear drops) in some jurisdictions. This formulation is used to treat bacterial infections of the ear canal.


Q: How does Levomycetin usage differ for infants under 2 years old?

A: For systemic use, the dosage for infants must be significantly reduced compared to adult doses. This adjustment is mandatory because infants have immature liver metabolism, which can lead to high drug levels and increase the risk of serious side effects like Gray Syndrome. In many places, topical use for children under 2 years requires a prescription.


Q: Is Levomycetin usage different or restricted for elderly patients?

A: Official administration guidelines note that the systemic dosage requires careful adjustment for elderly patients. This is typically done to account for potential changes in organ function that may affect how the medicine is cleared from the body.


Q: Can I wear contact lenses while using Levomycetin eye drops or ointment?

A: No, official guidance advises that contact lenses should not be worn while using Levomycetin eye drops or ointment. This guidance is generally issued to prevent irritation and absorption complications, as contact lenses can trap medication or preservatives.


Q: Are there guidelines for when a person can resume wearing contact lenses after treatment?

A: Official guidance suggests that if a person uses soft contact lenses, they should wait at least 24 hours after finishing the full course of the eye drops or ointment before putting them back in.


Q: Is it safe to drink alcohol while using Levomycetin?

A: Official regulatory summaries advise caution regarding the use of alcohol while taking Levomycetin. This caution is often issued because the combination of alcohol with this medicine may increase effects like drowsiness or mental confusion, which are documented nervous system side effects.


Q: Does Levomycetin interact with other types of prescription eye drops or ointments?

A: Official product information suggests that concomitant use of other prescription eye drops or ointments is a factor that should be discussed with a healthcare provider. This is standard procedural guidance to ensure the medicines do not interact physically or affect absorption.


Q: Is it necessary to throw away the bottle or tube of medicine after the treatment course is complete?

A: General official guidelines for safe drug disposal recommend that unused or expired medicine should be mixed with an undesirable substance, such as dirt or used coffee grounds, and then sealed in a plastic bag or container before being placed in the household trash. This helps prevent accidental ingestion.


Q: Why is it important to wash hands before and after applying Levomycetin drops or ointment?

A: Official procedural guidance emphasizes the importance of washing hands before and after application. This helps prevent the transfer of germs to the eye or ear, and prevents contaminating the tip of the dropper or tube, which helps keep the medicine itself as germ-free as possible.


Q: Is it true that Levomycetin should not be used for minor infections?

A: Yes. Official regulatory warnings state that Levomycetin should not be used for the treatment or prevention of minor infections. This warning is in place to ensure the medicine is reserved for appropriate and necessary bacterial infections, consistent with the cautious approach to its use.


Q: Is Levomycetin used to treat infections that are resistant to other antibiotics?

A: The classification of systemic Levomycetin as a 'last resort' medication often relates to its effectiveness against certain severe infections that may be caused by pathogens resistant to more commonly used, less toxic antibiotics. Its use is generally reserved for these specific situations.


Q: Can Levomycetin cause a secondary infection like oral thrush (candidiasis)?

A: Official information suggests that because the eye drops and ointment primarily work locally where they are applied, they are unlikely to cause a systemic secondary infection such as oral thrush (candidiasis). Secondary infections are generally a greater concern with oral antibiotics.


Q: What does it mean if my skin or lips turn a blue/gray color during treatment?

A: A gray-blue or ashen color in the skin or lips is listed in safety materials as a primary physical sign of the serious toxic reaction known as Gray Syndrome. This condition, which is a serious concern in infants and neonates, is documented in safety materials as warranting immediate attention.


Q: Can I use Levomycetin if I have recently had eye surgery?

A: Official patient guidance advises consulting a doctor if a person has had a recent eye injury. Since recent surgery involves a wound, official guidance advises that this factor should be assessed by a healthcare provider before the medicine is used.


Q: Are there specific symptoms that indicate the drug is causing bone marrow suppression?

A: Official safety materials indicate that bone marrow suppression can manifest through specific symptoms. These include unusual fatigue, fever, sore throat or other signs of infection, and easy bruising or bleeding gums.


Q: Is there a difference between prescription and over-the-counter Levomycetin preparations?

A: In some jurisdictions, the eye drops and ointment sold over-the-counter in pharmacies are the same strength as those available by prescription. A key regulatory difference is that a prescription is typically required for their use in children under 2 years of age.

How should Levomycetin be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict requirements for storing and disposing of Levomycetin (Chloramphenicol) to ensure stability and safety.

Storage Conditions

Requirement Specific Instruction
Temperature Varies by form: store capsules below 30 C. Ophthalmic forms may require storage below 25 C or refrigeration (2 C to 8 C).
Protection Keep in the original, tightly closed container, protected from light, moisture, and freezing.
Child Safety Must be kept locked up and out of the sight and reach of children.

Stability and Disposal

Requirement Specific Instruction
In-Use Stability Ophthalmic preparations must be discarded 28 days after opening. Single-use vials must be discarded immediately after use.
Disposal Rule Unused or expired medicine must not be disposed of in household trash or poured down a drain. All waste must be disposed of according to local regulatory requirements for unused medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levomycetin found in:

A-Z Index: